Gemini Therapeutics (GMTX) Financials

$23.93

$2.71 (12.77%)

As on 17-Feb-2023 09:30EDT

Market cap

$58 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	43.89	69.00	-0.82	--	--	--
Operating Profit (EBIT)	-43.89	-69.00	-34.04	--	--	--
Other Income	0.50	--	--	--	--	--
Profit before Tax	-43.42	-71.87	-0.81	--	--	--
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	-43.42	-71.87	-0.81	--	--	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-43.42	-71.87	-40.84	-41.40	-20.17	--

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	104.57	124.84	117.27	--	--	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	0.76	4.23	--	--	--
Current Liabilities	1.46	14.83	0.60	8.99	4.33	--
Total Liabilities	108.70	140.44	122.09	--	--	--

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	1.37	0.34	120.75	--	--	--
Current Assets	104.66	140.10	1.34	5.23	20.56	--
Total Assets	107.50	140.44	122.09	--	--	--
Total Debt*	--	5.40	--	--	--	--
Net Current Assets	103.20	125.27	0.74	--	--	--

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-59.70	-32.71	-38.53	-18.34	--
Cash Flow from Investing Activities	--	0.34	-0.02	-0.23	-0.43	--
Cash from Financing Activities	--	191.48	34.25	23.22	30.50	--
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-58.07	-1.39	--	--	--
ROE (%)	-40.17	-59.37	-0.69	--	--	--
ROA (%)	-31.50	-54.75	-0.67	--	--	--
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	-8,666.87	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	20.08	-8,479.87	98.03	-104.18	--	--
Net Profit Growth (%)	20.85	-8,745.47	--	--	--	--
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	--	--	--	--	--
Price / Book Value	0.68	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.79	1.89	2.47	--	--	--
Close Price ($)	16.40	29.10	110.00	--	--	--
High Price ($)	41.63	190.85	126.00	--	--	--
Low Price ($)	11.60	22.80	98.00	--	--	--
Market Cap ($ Cr)	58.49	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	0.04	--	--	--	--
Short term debt to equity ratio	--	0.04	--	--	--	--
Current Ratio	71.49	9.44	2.24	0.58	4.74	--
Quick Ratio	71.49	--	--	--	--	--
Interest Coverage	-179.92	-32.30	-0.12	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.